Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor - Wikidata - wikimedia - TriplyDB

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

http://www.wikidata.org/entity/Q28368986

about

The chemical biology of protein phosphorylation The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 Electrophilic affibodies forming covalent bonds to protein targets Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes ErbB receptors: from oncogenes to targeted cancer therapies Developing irreversible inhibitors of the protein kinase cysteinome In situ assembly of enzyme inhibitors using extended tethering Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity 6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases Identification of Cys255 in HIF-1α as a novel site for development of covalent inhibitors of HIF-1α/ARNT PasB domain protein-protein interaction Electrophilic Fragment-Based Design of Reversible Covalent Kinase Inhibitors Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles Discovery of Novel Irreversible Inhibitors of Interleukin (IL)-2-inducible Tyrosine Kinase (Itk) by Targeting Cysteine 442 in the ATP Pocket CEACAM1 modulates epidermal growth factor receptor--mediated cell proliferation From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents.A functional screen for genes inducing epidermal growth factor autonomy of human mammary epithelial cells confirms the role of amphiregulin.Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells.TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation.A liquid chromatography mass spectrometry assay for determination of PD168393, a specific and irreversible inhibitor of erbB membrane tyrosine kinases, in rat serum Roles of specific membrane lipid domains in EGF receptor activation and cell adhesion molecule stabilization in a developing olfactory system.Receptor type protein tyrosine phosphatase-kappa mediates cross-talk between transforming growth factor-beta and epidermal growth factor receptor signaling pathways in human keratinocytes Epidermal growth factor receptor inhibitor ameliorates excessive astrogliosis and improves the regeneration microenvironment and functional recovery in adult rats following spinal cord injury Detecting intratumoral heterogeneity of EGFR activity by liposome-based in vivo transfection of a fluorescent biosensor Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction.Overexpression of ErbB2 in cancer and ErbB2-targeting strategies.A small molecule inhibitor of endoplasmic reticulum oxidation 1 (ERO1) with selectively reversible thiol reactivity.A structure-guided approach to creating covalent FGFR inhibitors Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy.Targeting the EGFR signaling pathway in cancer therapy.Cellular signalling pathways: new targets in leukaemia therapy.Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides.Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.Anti-epidermal growth factor receptor drugs in cancer therapy.Propagation of human prostate cancer stem-like cells occurs through EGFR-mediated ERK activation.Phosphoproteomic analysis of Her2/neu signaling and inhibition.Developing inhibitors of the epidermal growth factor receptor for cancer treatment.ERBB receptor tyrosine kinases and cellular radiation responses.Oncogenes in thyroid cancer.

P2860

Q24620636-F96EC2D9-A81C-4AFB-AD50-35775378199F Q24633214-6D579F3B-CCD4-4F87-B5D7-60C437BC5651 Q24633878-D2A79CC3-2970-4248-B643-A18ECFD7F672 Q24651974-B8087A75-5E15-482E-B269-A7B1DEA2E94B Q24680869-EFE227D2-54A5-4409-AC1F-2284955D1FC9 Q24683709-077DB159-28E3-4BFF-AD22-BB146CE75EA7 Q27027983-13603089-B8FC-4CCB-8442-72F2D42DF8A2 Q27640418-C9312DFD-3020-44C5-93EB-EE3644006CD5 Q27644014-E017A6F7-D04E-4CEC-8161-54AB7E925195 Q27649889-1B2D6793-9EB3-43C7-84AA-7E41103A873F Q27652488-731B6B8B-FD12-4191-AF1F-7ADF405A7628 Q27674057-86971502-BC26-489E-93EC-1A64D5AD841D Q27677115-A733015A-2ABE-4701-B8EF-261BD3311DB6 Q27678280-3DD54668-42FC-438A-A11B-650E78E36257 Q27679513-835FDF58-2CBF-4240-8A31-A9024BEB6D0E Q28116188-FA4049B0-DCD3-4B7D-93E2-EDD9C63B53C0 Q30168082-9A567E6A-31BF-4024-A87B-81FB9737D1BD Q30999913-F733CA88-04D5-4C1E-A4B0-05257FD4629D Q31150111-DE6901AB-08FE-4316-8E9C-154305532A25 Q33348778-35D5B2A7-FCF1-4469-9E78-81E2CD7470DF Q33441373-B1BFE5D8-1CD4-48E4-A1D5-261CC3A4646D Q33507260-CAD994A7-B4C0-473D-83CD-06F4E024C74F Q33571636-C72F3D10-E57B-4E80-BF6F-044912BA475E Q33647461-DFF1C970-5CF6-4A10-9B60-C2990254B229 Q33647681-B0B9FE2D-5FA6-43E4-9904-067F851D1711 Q33777888-387585AD-9BE8-4005-A4D0-9A6A65BE8562 Q33931164-5C0C2DB4-3107-4584-9EE5-784BC538E511 Q33966806-FDA34C1C-CC18-462B-A1CD-50B37A994A25 Q34061522-F7C97C16-EB2A-4BF5-99D9-82CCF4F80115 Q34088024-199A7E87-8FC6-42F6-9F4F-4E789C7072BA Q34246558-7012AD7C-35BA-4E7C-8D04-704FE09C77CD Q34527660-B70E8DFC-6702-4689-88D5-95B87AB25C47 Q34573054-DCB509E2-B0E7-417C-823D-740D04936545 Q34625315-87B1FFD6-204F-4D88-BA30-42ED9DC45767 Q34660837-8F85CAEE-2F61-461D-B0AE-F7C930686372 Q34689170-94B4D6BA-9F6F-480C-B96E-CF5C3CCB5937 Q34772747-3D9B1039-1A06-4438-9A4D-7D4469C6DC54 Q35157038-59E4A1CA-F991-4342-B656-1F28654D922D Q35208821-E0AB54B2-13A7-44DF-A23F-B932DE5A7B90 Q35217001-09677D15-8F1B-451A-8C64-239F4ADC068B

P2860

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

http://www.wikidata.org/entity/Q28368986

description

1998 nî lūn-bûn

@nan

1998 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

1998 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

name

Specific, irreversible inactiv ...... s of tyrosine kinase inhibitor

@ast

Specific, irreversible inactiv ...... s of tyrosine kinase inhibitor

@en

Specific, irreversible inactiv ...... s of tyrosine kinase inhibitor

@nl

type

label

Specific, irreversible inactiv ...... s of tyrosine kinase inhibitor

@ast

Specific, irreversible inactiv ...... s of tyrosine kinase inhibitor

@en

Specific, irreversible inactiv ...... s of tyrosine kinase inhibitor

@nl

prefLabel

Specific, irreversible inactiv ...... s of tyrosine kinase inhibitor

@ast

Specific, irreversible inactiv ...... s of tyrosine kinase inhibitor

@en

Specific, irreversible inactiv ...... s of tyrosine kinase inhibitor

@nl

P1433

Q28368986-D449110C-96E7-4BD1-A74A-70080680EDA8

P1476

Q28368986-42459CF2-3E6D-49D9-9CBA-D8007C93EE01

P2093

Q28368986-225AF88F-A9E1-4AD8-8AF6-1894C9A09577

Q28368986-29709BEC-5411-48BC-B149-35C7BB302CCE

Q28368986-2A51A659-BFCB-4B0C-A0BD-EF5FC049994F

Q28368986-2A7A60F0-CB4C-4A21-827C-8A7919455D98

Q28368986-2F139E2D-8749-4587-91C7-13DDCF4E729B

Q28368986-5B0E405F-2982-42B7-8B18-3704D6A44B37

Q28368986-6653C4F8-4898-4CD3-9C90-42501E6C9107

Q28368986-70589E0E-FC44-4C13-A766-E6EBDF12BE67

Q28368986-729FBA57-2282-476C-98FC-41F1BF60815B

Q28368986-7EE9EDAE-6B4E-4A40-B695-733DAE3F369C

P2860

Q28368986-08432B94-3384-4BE0-89B1-815A897D1CF8

Q28368986-0C5DEFEC-F9FF-4509-9E45-FD024DA89F83

Q28368986-0D059E4D-D8DA-4A4E-B911-D5B39BFE1278

Q28368986-1827EF3F-CA8E-4E1F-B05C-3042C4431840

Q28368986-24621722-6C69-476B-A409-57B254C19A79

Q28368986-37718B52-3BB5-451B-B5A6-C8A339BBDE2C

Q28368986-3ECA7681-18E0-46C9-9180-E9F234E68C31

Q28368986-3F54215F-E418-4362-9A76-E4F2A6107FB8

Q28368986-5068F6B8-A65B-413E-865F-1D34130E761B

Q28368986-56DC6DA7-C7D4-4C5E-9735-7EC8498CF7C6

P304

Q28368986-AADC233F-AE57-4383-82B1-97D9B8749417

P31

Q28368986-1CF2DE20-66C8-41F4-9625-0E7A2A42DA9B

P356

Q28368986-E646D9A9-80E8-448A-899A-29298B5CB569

P407

Q28368986-9A2C652D-D304-4BD7-A4F8-E8DAC062A9EE

P433

Q28368986-B3EABFDD-1EB6-47C5-9804-EA03D168F14D

P478

Q28368986-24B6B3F3-A45C-4428-BDCA-CCD3FC58A32A

P577

Q28368986-26592391-D4EB-456C-A3EB-E61FAFF11776

P5875

Q28368986-44545B25-F672-4AA5-978D-38E6A2E272F0

P698

Q28368986-929E4BE4-36AD-4E06-B5EA-29F3B8AEF12C

P932

Q28368986-7FFF6C6F-5B8D-490E-939A-8CCEA629A829

P356

PNAS.95.20.12022

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Specific, irreversible inactiv ...... s of tyrosine kinase inhibitor

@en

P2093

A Doherty

http://www.w3.org/2001/XMLSchema#string

A J Bridges

http://www.w3.org/2001/XMLSchema#string

D J McNamara

http://www.w3.org/2001/XMLSchema#string

D W Fry

http://www.w3.org/2001/XMLSchema#string

E M Dobrusin

http://www.w3.org/2001/XMLSchema#string

J A Loo

http://www.w3.org/2001/XMLSchema#string

J B Smaill

http://www.w3.org/2001/XMLSchema#string

J L Hicks

http://www.w3.org/2001/XMLSchema#string

J M Nelson

http://www.w3.org/2001/XMLSchema#string

K D Greis

http://www.w3.org/2001/XMLSchema#string

P2860

Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions

Contributions of mass spectrometry to peptide and protein structure.

The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients.

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.

Bivalence of EGF-like ligands drives the ErbB signaling network

Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy.

The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer

Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma.

Structural features that specify tyrosine kinase activity deduced from homology modeling of the epidermal growth factor receptor.

Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice.

P304

12022-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.95.20.12022

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P577

1998-09-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13533769

http://www.w3.org/2001/XMLSchema#string

P698

9751783

http://www.w3.org/2001/XMLSchema#string

P932

21758

http://www.w3.org/2001/XMLSchema#string